A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Trial Profile

A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Clofarabine; Crisantaspase; Crisantaspase; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Etoposide; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Mitoxantrone; Nelarabine; Pegaspargase; Pegaspargase; Vincristine
  • Indications Acute lymphoblastic leukaemia; Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2015 Planned end date changed from 1 Dec 2018 to 1 Apr 2019, as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019, as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top